Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure

Journal of Heart and Lung Transplantation

Volumn 24, Issue 12, 2005, Pages 2196-2201

  Tallaj, José A ^a,b   Franco, Verónica ^b   Rayburn, Barry K ^b   Pinderski, Laura ^b   Benza, Raymond L ^b   Pamboukian, Salpy ^b   Foley, Brian ^b   Bourge, Robert C ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; SPIRONOLACTONE; WARFARIN;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG POTENCY; FEMALE; HEALTH PROGRAM; HEART FAILURE; HEART LEFT VENTRICLE EJECTION TIME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DOXORUBICIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 29144523934     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.12.108     Document Type: Article

References (21)

1. D. Van Hoff, M. Layard, P. Basa Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
2. D. Van Hoff, M. Rozencweig, M. Piccart The cardiotoxicity of anticancer agents Semin Oncol 9 1982 23 33
3. A. Allen The cardiotoxicity of chemotherapeutic drugs Semin Oncol 19 1992 529 542
4. P. Singal, N. Iliskovic Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900 905
5. J. Wojtacki, E. Lewicka-Nowak, K. Lesniewski-Kmak Anthracycline-induced cardiotoxicity clinical course, risk factors, pathogenesis, detection and prevention - review of the literature Med Sci Monit 6 2000 411 420
6. E.A. Lefrak, J. Pitha, S. Rosenheim A clinicopathologic analysis of Adriamycin cardiotoxicity Cancer 32 1973 302 314
7. A. Luthy, M. Furrer, M. Waser Orthotropic heart transplantation as efficient treatment in a young boy with doxorubicin-induced cardiomyopathy J Heart Lung Transplant 11 1992 815 816
8. M. Arico, L. Nespoli, E. Pedroni Heart transplantation in a child with doxorubicin-induced cardiomyopathy N Engl J Med 319 1988 1353
9. M.A. Pfeiffer, E. Baronial, L.A. Moyer Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the survival and ventricular enlargement trial - the SAVE investigators N Engl J Med 327 1992 669 677
10. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
11. M. Packer, M.R. Bristow, J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med 334 1996 1349 1355
12. A. Hjalmarson, S. Goldstein, B. Fagerberg Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF) JAMA 283 2000 1295 1302
13. B. Pitt, F. Zannad, W. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 754
14. M.R. Bristow, M.E. Billingham, J.W. Mason Clinical spectrum of Anthracycline antibiotic cardiotoxicity Cancer Treat Rep 62 1978 873 879
15. J. Saini, M.W. Rich, A.P. Lyss Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases Ann Intern Med 106 1987 814 816
16. M. Cohen, I. Kronzon, A. Lebowitz Reversible doxorubicin-induced congestive heart failure Arch Intern Med 142 1982 1570 1571
17. S.E. Lipshultz, S.R. Lipsitz, S.E. Sallan Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer J Clin Oncol 20 2002 4517 4522
18. R.E. Shaddy, S.L. Olsen, M.R. Bristow Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients Am Heart J 129 1995 197 199
19. S. Fazio, E.A. Palmieri, B. Ferravante Doxorubicin-induced cardiomyopathy treated with Carvedilol Clin Cardiol 21 1998 777 779
20. A. Noori, J. Lindenfeld, E. Wolfel β-blockade in Adriamycin-induced cardiomyopathy J Card Fail 6 2000 115 119
21. M. Bristow β-Adrenergic receptor blockade in chronic heart failure Circulation 101 2000 558 569